Other Information
−Removed: On October 28, 2025, the Company entered into an amendment to the Letter Agreement and the Support Letters with certain March 2025 Private Placement Purchasers (the “Amendment Agreement”), pursuant to which (a) the Support Letters were terminated other than with respect to the participation rights granted therein, and (b) the repayment mechanism under the Letter Agreement was modified.
−Removed: As modified, the Company is no longer required to use 90% of the proceeds from any subsequent financing to repay the March 2025 Private Placement Purchasers.
−Removed: Instead, the Company is only required to retain sufficient funds in an interest bearing account to cover such repayment obligations and make such repayments upon request by any March 2025 Private Placement Purchaser who executed the Amendment Agreement until each such purchaser has received cash either from the Company or from reselling securities acquired in the March 2025 Private Placement in an amount equal to 115% of the purchase price such purchaser paid in the March 2025 Private Placement.
−Removed: If such requests are made, the requesting purchaser must return shares acquired in the March 2025 Private Placement at a value of $0.66 per share.
−Removed: The foregoing summary does not purport to be complete and is qualified in its entirety by reference to the full text of the Amendment Agreement, which is filed as Exhibit 10.3 to this Quarterly Report on Form 10-Q.
+Added: On May 12, 2026, the Company filed a Certificate of Correction (the “Certificate of Correction”) to a Certificate of Amendment to the Amended and Restated Certificate of Incorporation of the Company (the “Certificate of Amendment”) that was previously filed on April 1, 2026.
+Added: The Certificate of Amendment erroneously stated the number of authorized shares of common stock, par value $0.001 per share, of the Company (“Common Stock”) as 200,000,000 (two hundred million).
+Added: As corrected by the Certificate of Correction, the total number of authorized shares of Common Stock is two billion (2,000,000,000).
EXHIBIT INDEX
11 unchanged sentences
Certificate of Amendment to the Certificate of Incorporation, as amended
+Added: Certificate of Amendment to the Amended and Restated Certificate of Incorporation, filed with the Delaware Secretary of State on April 1, 2026
+Added: Certificate of Correction to the Amended and Restated Certificate filed with the Delaware Secretary of State on May 12, 2026
Amended and Restated Bylaws of Plus Therapeutics, Inc.
1 unchanged sentence
Certificate of Designation of Preferences, Rights and Limitations of Series C Convertible Preferred Stock
+Added: 2020 Stock Incentive Plan, as amended and restated on May 14, 2026
Description of Securities
8 unchanged sentences
Form of Amended March 2025 Series B Warrant
−Removed: Form of Support Letter, dated July 11, 2025, by and between Plus Therapeutics, Inc.
−Removed: and certain holders
−Removed: Exhibit 10.41
−Removed: Amended & Restated 2020 Stock Incentive Plan, amended August 7, 2025
−Removed: Form of Amendment Agreement, dated October 28, 2025
+Added: Form of Warrant, dated January 15, 2026
Certification of Principal Executive Officer Pursuant to Securities Exchange Act Rule 13a-1.04(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
9 unchanged sentences
PLUS THERAPEUTICS, INC.
−Removed: October 30, 2025
President & Chief Executive Officer (Duly Authorized Officer and Principal Executive Officer)
/s/ Andrew Sims
−Removed: October 30, 2025
Chief Financial Officer (Duly Authorized Officer and Principal Financial Officer and Principal Accounting Officer)
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.